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Abstract
Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the recent addition of
nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of Essential Medicines against second stage HAT,
where parasites have invaded the central nervous system (CNS). The pharmacology of a potential orally available lead
compound, N-methoxy-6-{5-[4-(N-methoxyamidino) phenyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated in a vervet
monkey model of second stage HAT, following promising results in mice. DB844 was administered orally to vervet monkeys,
beginning 28 days post infection (DPI) with Trypanosoma brucei rhodesiense KETRI 2537. DB844 was absorbed and
converted to the active metabolite 6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-nicotinamide (DB820), exhibiting plasma
Cmax values of 430 and 190 nM for DB844 and DB820, respectively, after the 14th dose at 6 mg/kg qd. A 100-fold reduction
in blood trypanosome counts was observed within 24 h of the third dose and, at the end of treatment evaluation
performed four days post the last drug dose, trypanosomes were not detected in the blood or cerebrospinal fluid of any
monkey. However, some animals relapsed during the 300 days of post treatment monitoring, resulting in a cure rate of 3/8
(37.5%) and 3/7 (42.9%) for the 5 mg/kg610 days and the 6 mg/kg614 days dose regimens respectively. These DB844
efficacy data were an improvement compared with pentamidine and pafuramidine both of which were previously shown to
be non-curative in this model of CNS stage HAT. These data show that synthesis of novel diamidines with improved activity
against CNS-stage HAT was possible.
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Introduction
Human African trypanosomiasis (HAT, sleeping sickness) is a
debilitating disease that is caused by the protozoan parasites,
Trypanosoma brucei gambiense and T. b. rhodesiense. The disease is
transmitted by tsetse flies (Glossina spp) and is therefore endemic
only in geographical areas (foci) where both the parasite and
vector are present; these foci are distributed in ,20 sub-Saharan
African countries and are home to at least 50 million people who
are at risk of contracting HAT [1]. The spatial and temporal
distribution of HAT is further determined by emergence of
virulent parasite strains, breakdown in control and/or surveillance
activities, changes in climate and vegetation and movements of
carrier livestock species across borders [2]. As a result, the
epidemiology of HAT is characterised by periodic epidemics
interspersed with periods of near total eradication [3]. In 2009, the
annual incidence dropped below 10,000 reported cases for the first
time in 50 years, a success credited to the World Health
Organization (WHO), national disease control programmes,
bilateral co-operation and non-governmental organizations [4].
However, control activities must be maintained and new
diagnostics and drugs developed to have a realistic chance of
eventually eliminating HAT, a disease which has a history of
reversing previous gains [2,5–7].
Modern drug research and development activities for HAT
have recently increased markedly, primarily through the efforts of
public private partnerships (PPP’s), which are funded by govern-
mental and philanthropic organizations. A first success of these
PPP’s is the nifurtimox-eflornithine combination therapy (NECT),
a product that has was recently added to the WHO essential
medicines list for the management of T. b. gambiense CNS-stage
infections [4,8]. In addition, the dimethoxyamidine prodrug
pafuramidine (DB289), a pentamidine-like compound developed
by the Consortium for Parasitic Drug Development (CPDD),
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became the first oral drug to enter phase III clinical trials for 1st
stage HAT [9]. Clinical and preclinical investigations on
pafuramidine (DB289) demonstrated that oral diamidine prodrugs
could achieve efficacy equal to or better than pentamidine in the
management of 1st stage HAT [9–12]. However, the development
program was terminated after some subjects (6%) in an extended
phase I clinical trial (14 day dose regimen of 100 mg bid)
developed delayed renal insufficiency [9]. Like pentamidine,
pafuramidine did not achieve cure against 2nd stage HAT in
animal models [11,12].
In an effort to develop a compound that was well tolerated and
with efficacy against 2nd stage HAT, a next-in-class dimethox-
yamidine prodrug, N-methoxy-6-{5-[4-(N-methoxyamidino) phe-
nyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated. Similar
to the biotransformation of DB289, DB844 was shown to be
sequentially O-demethylated and N-dehydroxylated in human liver
microsomes to form its active metabolite, 6-[5-(4-phenylamidino-
phenyl)-furanyl-2-yl]-nicotinamide (DB820) [13]. In mice, oral
DB844 appeared to be well absorbed and converted to DB820,
and cured all animals (5/5) in the GVR35 CNS model of HAT
[11]. In vitro, DB820 was a potent trypanocide with an IC50 value
of 2.4 ng/ml (5.2 nM) against T. b. rhodesiense STIB900 [11].
DB820 also accumulated in the DNA containing organelles and
bound to DNA molecules preferentially at AT rich sites, thus likely
sharing the same mechanism of action with pentamidine [14–16].
The purpose of this study was to further evaluate the potential of
DB844 as a novel oral treatment against 2nd stage HAT by
characterizing its pharmacology in vervet monkeys, a species
commonly used as a preclinical model for HAT [12]. The specific
study objectives were to (a) characterize the metabolic profile of
the prodrug in vervet monkey liver microsomes; (b) evaluate the
toxicity of orally administered DB844 in un-infected monkeys to
understand tolerability and to define an appropriate dose range for
efficacy studies in the monkey HAT model; and (c) evaluate the
pharmacokinetics, efficacy and safety of DB844 in the infected
vervet monkey model, which closely mimics human sleeping
sickness.
Materials and Methods
Ethics Statement
Studies were undertaken in adherence to experimental guide-
lines and procedures approved by the Institutional Animal Care
and Use Committee (IACUC), the ethical review committee for
the use of laboratory animals at the Trypanosomiasis Research
Centre of the Kenya Agricultural Research Institute (TRC-
KARI). The experimental guidelines also complied with National
guidelines of the Kenya Veterinary Association.
Trypanocidal Test Compound
The test compound N-methoxy-6-{5-[4-(N-methoxyamidino)
phenyl]-furan-2-yl}-nicotinamidine (DB844) (Figure 1) was syn-
thesized in the laboratory of Dr. David Boykin (Georgia State
University, Atlanta, GA, USA) as previously reported [17]. The
current study used DB844 (lot D, C19H19N5O3?3HCl?H2O) with a
purity of .95% as determined by both NMR [17] and high
performance liquid chromatography (HPLC)/UV (described
below). DB844 was supplied to KARI-TRC through CPDD in
the form of yellow powder in opaque and water tight bottles. Once
received, the drug containing bottle was wrapped in aluminium
foil and refrigerated at 4–8uC. Dosing formulations were prepared
daily by dissolving the drug in de-ionised distilled water to render
concentrations of 5 and 6 mg/ml. Reconstituted drug was
protected from light by wrapping drug-containing vials with
aluminium foil.
Trypanosome Isolate
A pleomorphic isolate, T.b rhodesiense KETRI 2537, a derivative
of EATRO 1989 that was isolated from a patient in Uganda by
direct inoculation of blood and lymph node aspirate into a monkey
and later cryopreserved at KARI- TRC [18], was used. This
isolate is the basis of the KETRI vervet monkey and mouse models
and has been widely used for drug efficacy trials [19,20].
Experimental Animals
Adult vervet monkeys [Chlorocebus (Cercopithecus) aethiops syn.
African green monkeys] (n = 22) weighing between 2.5 and 5.5 kg
were acquired from the Institute of Primate Research (IPR) in
Kenya. Monkeys were quarantined, screened, acclimated for the
study for a minimum of 90 days while being screened for evidence
of disease as previously described [12,20,21]. They were also de-
wormed, treated for ectoparasites, and acclimated to staying in
individual squeeze-back stainless steel cages and human handling.
The monkeys were fed a diet of fresh vegetables and commercial
monkey cubes (Unga feeds, Nakuru Kenya) twice daily and
provided water ad libitum.
Metabolism of DB844 in Vervet Monkey Liver
Microsomes
The metabolism of DB844 was investigated using liver
microsomes, prepared from a male vervet monkey by XenoTech,
LLC (Lenexa, KS), in the presence of NADPH as described
previously [22] with modifications. Briefly, incubation mixtures
(1 ml at pH7.4, in triplicate) contained 10 mM DB844 and
0.2 mg/ml monkey liver microsomes. After a 5-min equilibration
period at 37uC, reactions were initiated with the addition of
NADPH. Aliquots (50 ml) of the reaction mixtures were removed
at 0, 5, 10, 15, 30, 60, 90, and 120 min and mixed with 25 ml of
ice-cold acetonitrile. The mixtures were centrifuged (10,0006g for
5 min at 4uC) and the supernatants were analyzed by HPLC/UV
using the same method as previously described for DB289 [22].
Author Summary
New drugs are needed to treat sleeping sickness,
especially the second stage of the disease, which is
characterised by the presence of parasites (trypanosomes)
in the brain. The purpose of this work was to determine
whether DB844, a new drug that is converted to the active
form (DB820) after oral administration, has the potential to
treat second stage sleeping sickness. Two dosing regimens
of DB844 were evaluated in two groups of vervet monkeys
that were infected experimentally with trypanosomes.
Treatment was initiated four weeks after infection, when
the monkeys were in second stage sleeping sickness, as
confirmed by the presence of trypanosomes in brain fluid.
Orally administered DB844 was well absorbed, tolerated
and resulted in a decrease of trypanosomes in both the
blood and brain fluid. However, some monkeys relapsed
after treatment, with an overall cure rate of approximately
40% in both study groups. For at least two days after last
dosing, the active drug, DB820, achieved blood concen-
trations known to be at least 19 times more than the
minimum concentration that has been shown to be
effective against a stringent human infective trypanosome
isolate (STIB 900). These results represent an advance in
efforts to develop new related compounds as oral
treatments for sleeping sickness.
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Metabolite identification was performed by comparing retention
times to those of synthetic standards, which include M1A
(DB1284), M1B (DB1058), M2A (DB1285), M2B (DB1212), M3
(DB821), and DB820 [13]. DB844 and metabolites were
quantified using a single-concentration calibration curve generated
using synthetic standards.
Toxicity Study in Uninfected Monkeys
The toxicity of DB844 was evaluated in uninfected vervet
monkeys with the aim of defining the appropriate dose-range for
the compound, identifying target organs of toxicity and charac-
terizing the nature of drug-induced toxicity in this species. Six
monkeys were used to evaluate the tolerability of 10-day oral dose
regimens. Baseline clinical and haematology data were collected
during a 14-day period, after which two monkeys (one male and
one female) per dose group were administered with DB844 at 5,
10 or 20 mg/kg/day for 10 days via oral gavage. A dose volume of
1 ml/kg was administered. Daily ward rounds were conducted to
assess feed intake (appetite), demeanour, posture and stool
composition and consistency. Feed intake was assessed by scoring
the proportion of the daily ration consumed by each monkey
based on a scale of 1 (full ration eaten), 3/4, 1/2, 1/4 and 0 (no
feed eaten) as previously described [21].
Monkeys were monitored for 28 days post dosing. They were
anaesthetized through intramuscular (IM) injection with ketamine
HCl (10–15 mg/kg) and ValiumH (0.5 mg/kg) to facilitate
physical examination, body weight measurements and sample
collection. Blood was collected from the femoral vein via inguinal
venipuncture as described previously [20,23] and divided into
aliquots: 1 ml in EDTA for full haemogram determination and
2 ml in EDTA for plasma separation. Plasma was separated using
a cool spin centrifuge (4uC, 1500 revolutions/minute), separated
into aliquots and stored at 220uC pending analysis for DB844/
DB820 concentrations.
When overt drug related toxicity was detected, drug adminis-
tration was withdrawn from the affected monkey(s) to allow the
affected individuals to recover. Monkeys that failed to recover
were humanely euthanized using 20% pentobarbitone sodium
(EuthatalH, Rhone Merieux) for gross and histopathology exam-
ination. Euthanasia was carried out when monkeys were judged to
have deteriorated to the in extremis condition, characterised by
inability or reluctance to perch and very low feed intake (less than
1/4 of daily ration) for 2–3 consecutive days [21,24]. Organ
specimens from these monkeys were preserved in 10% formalin
and later sectioned for histopathogy. The processed slides were
stained with haematoxylin and eosin.
Monkey Infections
Sixteen vervet monkeys in two groups of eight monkeys each
(four males and four females) were used. After a 14-day baseline
weight, clinical and haematology data collection period, the
sixteen monkeys were infected by intravenous injection of
approximately 104 trypanosomes diluted from infected blood of
immuno-suppressed donor Swiss white mice [12]. Parasitaemia
post infection was determined by examination of wet film of ear
prick blood and/or examination of buffy coat after centrifugation
of blood collected in a heparinised capillary tube as described
previously [25]. Parasitaemia in wet film was estimated using the
rapid matching method of Herbert and Lumsden [26]. In
addition, monkeys were confirmed to be in second stage disease
by detection of trypanosomes in the CSF with or without elevated
white cell counts above 5 cells/ml [4,20,21,23]. At 28 days post
infection (DPI), the animals were treated with DB844 via oral
gavage at 5 mg/kg qd610 days (group I, n = 8) or 6 mg/kg
qd614 days (group II, n = 8), utilising a dose volume of 1 ml/kg.
The monkeys were examined for parasitaemia every day during
drug treatment and then twice weekly until $300 days post
dosing, at which point monkeys were considered cured if they
remained clinically normal and parasite-free as determined below.
Pre and Post Treatment Monitoring
Daily ward rounds were conducted throughout the study to
assess feed intake, demeanour, posture, and stool composition and
consistency. Feed intake was assessed by scoring the proportion of
the daily ration consumed by each monkey on a scale of 1 (full
ration eaten), 3/4, 1/2, J, and 0 (no feed eaten) as previously
described [21]. Monkeys were anaesthetised weekly by intramus-
cular injection of ketamine HCl (10–15 mg/kg) and ValiumH
(0.5 mg/kg) for physical examination, body weight measurements
and collection of whole blood in EDTA and cerebrospinal fluid
(CSF) samples. Blood samples (1 ml) were thereafter collected for
preparation of plasma for pharmacokinetic studies at 1, 2, 4, 8, 24,
48, 96 and 168 h and then weekly until 28 days, while CSF
samples (0.7–1.5 ml) were collected at 1, 24, 96, 168 h and then
weekly until 28 days post last dosing. Samples were collected by
inguinal venipuncture (blood) or lumbar puncture (CSF) of
anaesthetised monkeys as previously described [12]. Plasma was
separated using a cool spin centrifuge (4uC, 1500 RPM). After 28
days post last dosing, blood and CSF samples were collected once
every two weeks up to 100 days, then once per month until 300
days post dosing for haematology and parasite detection only.
During sampling, some of the free-flowing CSF was collected into
a capillary tube and immediately transferred onto a haemocy-
tometer (Neubaeur) chamber for counting of trypanosomes and/
or white blood cells. Samples that were negative for CSF
trypanosomes by direct microscopy were concentrated and
examined according to the modified single centrifugation
technique [21,27]. All the CSF samples that remained negative
for trypanosomes after the concentration step were then sub-
inoculated into Swiss white mice (2 mice per sample) to further aid
in diagnosis of infected fluids. Similarly, blood samples that were
negative for trypanosomes after concentration [26] were inocu-
lated into Swiss white mice. When trypanosomes were detected in
blood and/or CSF or when monkeys were diagnosed to have
attained in extremis condition as previously described [21,24], they
were humanely euthanized using 20% pentobarbitone sodium
(EuthatalH, Rhone Merieux) for post mortem examination.
Figure 1. Chemical structure of DB844 and DB820.
doi:10.1371/journal.pntd.0001734.g001
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Haematology samples (1 ml) were analysed using an AC3diffT
Coulter Counter (Miami, Florida, USA). Clinical chemistries were
determined using a Humalyzer analyser system. Finally, plasma
and CSF were analyzed for drug and metabolite concentrations
using an HPLC-tandem Mass Spectrometry (HPLC-MS/MS)
procedure as described below.
Sample Preparation and HPLC-MS/MS Quantification
Monkey plasma and CSF samples were prepared and quantified
for DB844 and DB820 using previously described methods [22,28]
with modifications. Briefly, plasma or CSF samples (25 ml) were
extracted with 200 ml of 7:1 (v/v) methanol:water containing 0.1%
(v/v) trifluoroacetic acid and deuterated internal standards (30 nM
each for DB844-d4 and DB820-d4), followed by centrifugation,
evaporation, and reconstitution before HPLC-MS/MS analysis
[28]. HPLC-MS/MS quantification of DB844 and DB820 was
performed on an Applied Biosystems (Foster City, CA) API 4000
triple quadruple mass spectrometer equipped with a Turbo
IonSpray interface in positive ion mode (MDS Sciex, San
Francisco, CA). Reconstituted samples (4–5 ml) were separated
on an Aquasil C18 analytical column 2.1650 mm, 5 mm (Thermo
Electron, Waltham, MA) with mobile phases consisting of HPLC-
grade water containing 0.1% formic acid (A) and methanol
containing 0.1% formic acid (B). After a 0.4-min initial hold at
15% B, mobile phase composition began with 15% B and was
increased to 80% B over 1.6 min, followed by a 1.0-min hold, at a
flow rate of 0.5 ml/min. The column was then washed with 95%
B for 1.3 min at a flow rate of 0.5 ml/min and was re-equilibrated
with 15% B at a flow rate of 0.5 ml/min for 0.5 min before
injection of the next sample. The characteristic SRM transitions
for DB844 and DB820 were m/z 366.2R319.2 and
306.2R289.2, respectively. The calibration curves for DB844
ranged from 2.5–2500 nM and 1–1000 nM in plasma and CSF,
respectively, using a quadratic equation with 1/x weighting. The
calibration curves for DB820 ranged from 10–2500 nM and 1–
1000 nM in plasma and CSF, respectively, using a quadratic
equation with 1/x weighting.
Data Analysis
Data were analysed statistically using Statview for Windows
Version 5.0.1 (SAS Institute Inc, Cary, NC). Repeated measures
ANOVA, with Fishers PLSD post hoc test, was used to test the
effects of trypanosomal infection, as well as DB844, on haema-
tology and clinical chemistry parameters in comparison with
respective baseline values (a= 0.05). Confidence intervals [95%]
were derived to further test the significance of observed findings.
Pharmacokinetic outcomes were determined using standard non-
compartmental methods performed using Phoenix WinNonlin
(version 6.2, Pharsight, Mountain View, CA).
Results
Metabolism Profiles in Monkey Liver Microsomes
DB844 was rapidly metabolized in vervet monkey liver
microsomes (MLM) with a microsomal half-life of approximately
14 min to form at least seven metabolites over a 120 min
incubation period (Figure 2). The first two metabolites to be
detected, M1A and M1B, were likely formed through the oxidative
O-demethylation of either the pyridyl or phenyl side of DB844
[13]. M1A and M1B gave rise to M2A and M2B respectively,
through reductive N-dehydroxylation, or further O-demethylation
to form the bis-amidoxime metabolite, M3. The O-demethylation
of M2A and M2B resulted in M4A and M4B, respectively, which
could also be generated by N-dehydroxylation of M3. At last, the
N-dehydroxylation of M4A and M4B gave rise to the active
metabolite DB820 (Figure 2). Metabolites M1A and M1B attained
the highest concentrations during the initial 20 minutes of
incubation after which M3 became the metabolite with the
highest concentration in the drug/liver microsome mixture
(Figure 2).
Toxicity
Uninfected monkeys were orally dosed with DB844 at 5, 10 or
20 mg/kg/day for 10 days. The lowest, 5 mg/kg, did not elicit
adverse clinical signs of toxicity in 2/2 monkeys (Table 1). Overt
toxicity was however observed in 1/2 and 2/2 monkeys to which
DB844 was administered at 10 and 20 mg/kg, respectively
(Table 1). In the high dose group, overt toxicity was confirmed,
at the earliest, after eight daily doses (cumulative dose
[CD] = 160 mg/kg). Drug administration to these monkeys was
immediately withdrawn to allow clinical recovery which, however,
did not occur. As a result, the monkeys were humanely euthanized
1–2 days later (9–10 days post first dosing) (Table 1). Both
monkeys from the middle (10 mg/kg) dose group completed the
10-day dose regimen successfully (CD = 100 mg/kg) after which
1/2 developed signs of overt toxicity and was eventually
euthanized 16 days post first dosing (Table 1). The adverse
clinical events included anorexia, gastrointestinal disturbances
(vomiting or changes in stool consistency), jaundice and weight loss
of up to 10.5% (Table 1). Haematology revealed nothing
significant except for vervet 578 (10 mg/kg); in this monkey, the
red cell distribution width (RDW) rose from 15 to 18.4 (23%) while
mean corpuscular volume (MCV) rose from 76.6 to 86.9 fl (13%).
At histopathology examination, lesions observed included inflam-
mation and erosions of the gastrointestinal tract (GIT), fatty
change (steatosis) in the liver, hydropic degeneration of renal
tubular cells and haemorrhage and haemosiderosis in multiple
organs (Table 1). Toxicokinetic analysis revealed that in the two
monkeys that were dosed at 5 mg/kg, DB844 and DB820
achieved average concentrations of 215 nM and 41.6 nM
respectively at 1 h post last dosing. However, other toxicokinetic
measurements could not be determined due to the limited
sampling.
Progression of the T.b. rhodesiense Infection
The pre-patent period of the experimental T. b. rhodesiense
infection in both groups of monkeys was approximately 5–6 days
(Table 2). Parasitaemia rose to a peak of 5.06107 trypanosomes
(antilog 7.7) within 2–3 days (7–8 DPI) but subsequently fluctuated
to give characteristic waves of parasitaemia (Figure 3). Monkeys
developed a classical T. b. rhodesiense clinical disease characterised
by reduction in feed intake, raised hair coats, reduced activity,
dullness and/or excitability when the clinical signs were first
observed at 4–7 DPI. Anorexia and inactivity were transient,
lasting a maximum of 3 days before normal appetite and activity
were regained. Enlargement of peripheral lymph nodes (especially
axillar and inguinal lymph nodes) and splenomegaly (up to 3 times
compared to pre-infection) were also observed 7–14 DPI while
facial, scrotal or eyelid oedema were observed in 8/16 (50%) of the
infected monkeys from 20 DPI. Average (6 SE) weight before
infection was 3.660.4 (range = 2.6–5.5) and 3.160.3 (range = 2.3–
4.2) kg for group I and II, respectively. Four weeks after infection,
weight decreased significantly (p = 0.0003) by 6.4% and 5.6%,
respectively. Time to parasitization of the cerebrospinal fluid
(CSF) was a median 21 days (range = 7–27) for both groups of
monkeys (Table 2). At 27 DPI, one day before initiation of
treatment with DB844, trypanosome numbers ranged from 1–8/ml
of CSF; median cell numbers were 5.0 (range = 0–45) and 6.0
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(range = 1–20) cells/ml of CSF in groups I and II respectively.
During previous weekly samplings, white cell counts in some
monkeys increased to 152/ml of CSF (Table 2).
Efficacy
At 28 DPI when monkeys had shown characteristic features of
2nd stage infection (i.e., presence of trypanosomes and elevated
white blood cell counts above 5/ml of CSF), they were treated with
DB844 at 5 mg/kg610 days (group I) or 6 mg/kg614 days (group
II). At 24 h post third drug dose (i.e., 4th day of treatment),
trypanosomes were not detected in wet smears of peripheral blood
(Figure 3), showing that at least 100-fold reduction in parasitaemia
had been achieved, from 107 to 105 trypanosomes/ml of blood
which is the detection limit of the matching method of Herbert
and Lumsden [23]. End of treatment (EoT) evaluation was
conducted at 1 and 4 days post last dosing time points. At the one
day post dosing time point, trypanosomes were detected in some
monkeys using sensitive trypanosome concentration techniques for
both blood and CSF [25,27] as evidenced by provisional cure rates
of 7/8 (group I) and 5/7 (group II) (Table 2). The three monkeys
with persisting low numbers of trypanosomes in the blood and/or
CSF eventually tested negative at the 4 days post dosing time point
(Table 2), demonstrating an EoT provisional cure rate of 100% for
both groups.
Post treatment follow-up was carried out for at least 300 days
post dosing. During this follow-up period, nine monkeys relapsed
demonstrating an overall test of cure rate of 3/8 (37.5%) and 3/7
(42.5%) for the 5 mg/kg and 6 mg/kg dose groups respectively
(Table 2). Trypanosomes were observed exclusively in the CSF in
five of the relapsed monkeys. In three of the four remaining relapse
cases, trypanosomes were detected in the CSF earlier than in the
blood. Overall, the median (range) time to trypanosome recru-
descence was 133 (35–322, n = 9) days for CSF and 261 (239–322,
n = 3) days for blood trypanosomes. Despite trypanosomes
becoming cleared from the peripheral blood by eighth day of
dosing, monkey 625 (Table 2) developed toxicity and was
humanely euthanized 2 days after administration of 10th dose of
DB844 at 6 mg/kg (CD = 60 mg/kg). At post mortem examina-
tion, liver and gastrointestinal toxicity were observed, comparable
to findings in 1/2 (10 mg/kg) and 2/2 (20 mg/kg) un-infected
monkeys euthanized due to DB844 toxicity.
Haematology Changes in the Infected Monkey Model
The trypanosome infection provoked a reduction in erythro-
cytes (red blood cells, RBC) and associated parameters. Average
haemoglobin concentration declined by 32.1% in group II
monkeys, from 13.460.6 [95% CI = 12.4–15.1] g/dl at baseline
(day 0) to 9.160.6 [95% CI = 7.9–10.3] g/dl (p,0.0001] at 27
DPI (Table 3). Erythrocyte counts and haematocrit concentration,
declined significantly (p,0.0001, Table 3) by 28.7% and 32.1%,
respectfully. Mean corpuscular volume (MCV) and mean corpus-
cular haemoglobin (MCH) decreased significantly (p,0.0001)
(Table 3). Erythrocyte associated parameters of group I monkeys
exhibited similar trends (data not shown), indicating that the
infection caused a microcytic hypochromic type of anaemia.
Monkeys also experienced significant thrombocytopenia and
leucopaenia (Table 3) related to the experimental T. b. rhodesiense
infection. Upon treatment with oral DB844, no drug related
haematology changes were observed. Trypanosome induced
anaemia, thrombocytopenia and leucopaenia resolved rapidly.
Baseline white cells numbers were re-established by end of
treatment while platelet and RBC associated parameters were
re-established within seven and 28–63 days respectively (Table 3;
Figure 4).
Clinical Chemistries
Plasma from infected monkeys treated with DB844 at 6 mg/kg
(group II) was analyzed for several biomarkers of liver and kidney
function. Plasma aspartate aminotransferase (AST) did not change
significantly following infection but peaked transiently during drug
administration (Figure 5, Figure S1). At 24 hours post dosing,
mean (6 SE) plasma AST increased to 3.3 times above baseline,
from 37.064.8 IU [95% CI = 26.7–46.8] (day 0) to 121621.6 IU
[95% CI = 65.5–176.5, p = ,0.0001]. Mean plasma alanine
aminotransferase (ALT) exhibited an increasing trend immediately
after infection (day 0) and peaked after 7 daily drug doses (34 DPI)
(Figure 5). At its peak, mean plasma ALT increased by 2.7 times
above baseline, from 4.560.9 IU [CI = 2.1–6.9] (day 0) to
13.663.8 IU [CI = 3.8–23.4; p = 0.008]. Aberrations in ALT
resolved rapidly after treatment. Monkeys further demonstrated a
significant infection-related 25.8% decrease in mean plasma
albumin concentration, from 35.361.9 [CI = 30.4–40.3] g/l at
baseline to 26.264.2 [95% CI = 15.4–37.0, p = 0.02] g/l at 27
DPI. Plasma albumin concentration stabilized during the treat-
ment period, then decreased transiently to a nadir at 48 h post
dosing (43 DPI, Figure 5). Total bilirubin and direct bilirubin
concentrations fluctuated in a pattern comparable to the
transaminases (Figure 5), but none of the changes were statistically
significant. Mean alkaline phosphatase was 6.361.9 at baseline
and 4.160.8 at 27 DPI (p = 0.25) and showed no significant
changes both during and after drug administration. Two
indicators of renal function, blood urea nitrogen (BUN) and
creatinine, were evaluated. BUN indicated a mild and reversible
decrease in kidney function from 48 h post dosing (43 DPI)
(Figure 5). Mean plasma concentration of creatinine fluctuated in
a similar pattern to BUN, but the change from baseline was not
significant (data not shown).
Pharmacokinetics
Plasma and CSF collected from group II monkeys (6 mg/kg)
were analyzed for various pharmacokinetic outcomes using
traditional non-compartmental methods. After the last (i.e. 14th)
dose of DB844, geometric mean (90% CI) concentrations of
DB844 peaked at 1 h in plasma with a Cmax of 430 (100–1800)
nM (Table 4, Figure 6) with modest individual animal variations in
PK profiles (Figure S2). The active metabolite, DB820, peaked at
4 h in plasma with a Cmax of 190 (110–320) nM. Exposure to
DB820 was three-fold higher than that of DB844, as assessed by
the metabolite:parent AUC ratio (Table 4). DB844 concentrations
decreased at a faster rate than DB820 concentrations, with a
geometric mean (90% CI) apparent terminal elimination half-life
of 5.8 (3.4–9.6) h. DB820 was detected in plasma up to 28 days
after the last dose of DB844 with a geometric mean (90% CI)
concentration of 35 (14–86) nM. Given the protracted decline in
Figure 2. HPLC/UV chromatograms and concentration-time profiles of DB844/metabolites following incubation of DB844 with
male vervet monkey liver microsomes. A: HPLC/UV chromatograms; B: Concentration-time profiles of DB844 and metabolites. Incubation
mixtures (1 ml at pH7.4, in triplicate) contained 10 mM DB844 and 0.2 mg/ml monkey liver microsomes. Aliquots were taken at 0.2, 5, 15, 30, and
120 min and evaluated for concentrations of DB844 and six metabolites (M1A, M1B, M2A, M2B, M3, and DB820). Metabolites M4A and M4B were not
quantified due to lack of synthetic standards.
doi:10.1371/journal.pntd.0001734.g002
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DB820 plasma concentrations, the duration of plasma collection
was insufficient for accurate estimation of the terminal half-life of
DB820 for all monkeys (Figure 6). DB844 was detected in CSF 1 h
post dose, with a geometric mean (90% CI) concentration of 17
(7.3–39) nM, and was not detected thereafter. DB820 was not
detected in the CSF, with only 2/7 monkeys (monkeys 571 and
624) showing sporadic low concentration (,4 nM) between 24
and 96 h post dose.
Discussion
The current study has shown that the novel diamidine prodrug
(DB844) was effectively metabolized by male vervet monkey liver
microsomes to yield at least seven metabolites which were also
detected when DB844 was incubated with human liver micro-
somes [13]. The order in which metabolites were generated in the
monkey liver microsomal/drug mixtures and their relative
concentrations, dominated by M1A (DB1284) and M1B
(DB1058) within the first 20 minutes and by M3 (DB821)
thereafter, were also similar to the pattern observed in human
liver microsomes [13] suggesting that vervet monkeys would be a
useful animal model for evaluation of a drug (DB844) that was in
development as a potential therapeutic agent for a human disease
(HAT). Our study did not investigate the enzymes responsible for
the conversion of DB844 to DB820. It has however been
previously shown that conversion of pafuramidine (DB289) to
furamidine (DB75) was catalysed by cytochrome P450 enzymes
and cytochrome b5/b5 reductase in the human liver [22,29]. Liver
microsomes derived from female vervet monkeys and Cynomolgus
monkeys metabolized DB844 as efficiently as those derived from
male vervets (data not shown), thus justifying evaluation of DB844
in monkeys.
The prodrug (DB844) was well tolerated when tested in
uninfected vervet monkeys at the lowest dose (5 mg/kg610 days)
but was toxic to both monkeys when administered at the highest
dose (20 mg/kg68 days). The middle dose (10 mg/kg610 days)
was well tolerated by 1/2 monkeys, suggesting that this dose was
slightly more than the maximum tolerated dose in uninfected
monkeys. Clinical signs of overt toxicity were detected either after
completion of dose regimen (10 mg/kg group) or late into the
treatment regimen (20 mg/kg group), suggesting that overt
toxicity was dependent on both the daily drug dose and duration
of drug administration. These results were consistent with a
previous report in which several pentamidine derivatives were
associated with acute to chronic toxicity in rodents, which was
cumulative in nature with respect to drug exposure [30]. The no
observed adverse effects level (NOAEL) for oral DB844 in un-
infected monkeys was therefore in the range 5–,10 mg/kg, and
as a result, daily dose levels of 5 and 6 mg/kg were chosen for the
subsequent efficacy study.
DB844/DB820 concentrations in plasma samples from un-
infected monkeys (5 mg/kg group), though limited in scope,
demonstrated that the prodrug was absorbed after oral adminis-
tration and converted to the active metabolite (DB820). Similarly,
when Cynomolgus monkeys were dosed orally with DB844 at 3 or
10 mg/kg, the drug was absorbed and the resulting plasma
DB844/DB820 concentration-time profiles were comparable to
those achieved in mice that were dosed at 25 and 100 mg/kg,
respectively (Michael Z. Wang, personal communication). These
findings were significant since DB844 at 25 or 100 mg/kg was
subsequently determined to be curative for 1st and 2nd stage
experimental murine HAT infections respectively [11], suggesting
that comparatively low dose levels could be efficacious in primates.
A period of dosing of 10–14 days was selected for the vervet
DB844 efficacy study, partly informed by a report that during
clinical trials of the related 1st stage investigational HAT drug
DB289, the duration of dosing had to be increased from 5 to 10
days in order to increase efficacy (Sonja Bernhard, Personal
communication). In addition, the fact that in humans 2nd stage
HAT is treated for 10 days with melarsoprol or NECT) and 14
days with intravenous eflornithine [4] was considered since these
dosing periods are partly influenced by the tissue invasive nature of
the human infective parasites.
Oral DB844 achieved up to 43% cure rate in the vervet monkey
model of 2nd stage HAT. Prior to initiation of treatment at 28 DPI,
all 16 monkeys in this study were confirmed to have trypanosomes
and pathological white cell numbers in their CSF, confirming that
the model fulfilled the criteria for classification of CNS (late, 2nd)
stage disease [4]. Pathophysiology studies have shown that
Figure 3. Parasitaemia pattern in monkeys infected with T.b. rhodesiense KETRI 2537 and subsequently treated with DB844. Symbols
and error bars represent means and SEs, respectively, of 7 animals; monkeys were treated with DB844 at 6 mg/kg614 days, from 28–41 days post
infection; Log parasitaemia values were determined by microscopic examination of wet smears of blood using the matching method of Herbert and
Lumsden, 1976 [23].
doi:10.1371/journal.pntd.0001734.g003
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trypanosome entry into the CSF initiates meningitis and leads to
elevated CSF nitric oxide and IgM concentrations, all further
indicating CNS disease [31,32]. Although occurrence of histolog-
ically demonstrable meningoencephalitis may not be guaranteed
in the course of primary T. b. rhodesiense infections [31,33], previous
studies have shown that when treatment was initiated at 28 DPI in
this monkey model, pafuramidine (DB289) and pentamidine did
not cure any monkey ([12]; unpublished TRC-KARI data). The
data reported in this study, therefore, indicates that DB844 had an
improved activity in the CNS stage monkey model compared to
the other diamidines.
Biological activity of orally administered chemotherapeutic
agents against tissue invasive parasites such as T. b. rhodesiense is
dependent upon absorption in the gut and attainment of effective
exposure levels of the prodrug and/or active metabolites in body
fluids and tissues. Pharmacokinetic evaluation of efficacy study
(6 mg/kg group) monkeys confirmed that marked DB844
concentration was attained in plasma within 1 hr of the last dose.
Peak plasma levels of DB820 were attained within 4 h post last
dosing showing that metabolic conversion of DB844 to DB820 was
comparable to previous observations in rats and cynomolgus
monkeys involving the related prodrug/active metabolite pair,
DB289/DB75 [34]. The peak plasma concentrations of the active
drug (DB820) were 37 times (190/5.2) higher than the IC50 for T.
b. rhodesiense STIB900; the DB820 concentrations remained at least
19 times (100/5.2) higher than the IC50 for T. b. rhodesiense
STIB900 for at least 48 h post dosing, suggesting that alternative
dose regimens in which the drug was dosed once every two days
may be sufficient for bloodstream trypanosomes. The plasma Cmax
achieved by DB844 in our study was significantly higher than the
30–35 nM Cmax values obtained when DB289 was dosed orally to
cynomolgus monkey at 5 mg/kg [34]), consistent with similar
observations when both DB844 and DB289 were dosed to mice
[35].
Detection of DB844 in the CSF indicated BBB penetration and
was likely responsible for observed reduction in trypanosome
densities in CSF of all monkeys to below the limit of detection for
varying periods and eventual cure of 3/7 (43%) group II monkeys.
The active metabolite (DB820) was, however, detected only
sporadically in CSF of two of the group II monkeys, one of which
was eventually cured and one of which was not. The discordance
between the CSF PK data and observed activity may result from
three possibilities: i) No CSF samples were collected between 1–
24 h post dosing. The reduced sampling time points, though
justified due to ethical considerations, may have resulted in
underestimation of DB820/DB844 in CSF; ii) Some of the
intermediate metabolites of DB844, including the monoamidines
DB1212, DB1285, M4A and M4B have been shown to have anti-
trypanosmal activity in vitro [11]. Unfortunately, these were not
quantified in the vervet CSF in our study; iii) trypanosomes were
shown to be capable of accumulating DB820 and DB75 up to
15,000 times above mouse plasma concentrations [36], suggesting
that trypanocidal drug concentrations could accumulate and
reduce the density of trypanosomes in CSF despite low concen-
trations of the active metabolite/s.
Trypanosome recrudescence in the CSF preceded that in the
blood (133 vs. 261 days), indicating that CSF/CNS remained a
major sanctuary/source of relapse trypanosomes despite the
improved efficacy of DB844 compared with other diamidines.
This was consistent with the generally low CSF: plasma ratio of
1:27 (3.7%) for DB844 at 1 h post last dosing. In addition, and in
spite of the limitations highlighted above, that DB820 was hardly
quantified in CSF while it was detected in plasma in relatively high
Figure 4. Changes in red cell distribution width in monkeys
following infection and subsequent treatment with DB844.
Symbols and error bars represent means and SEs, respectively, of seven
monkeys that were treated with DB844 at 6 mg/kg614 days, from 28–
41 days post infection.
doi:10.1371/journal.pntd.0001734.g004
Table 3. Haematologic effects of T. b. rhodesiense KETRI2537 infection and treatment with DB844 in vervet monkeys.
Parameters Days post infection (days post last drug dose)
0 27 41 (0) 48 (7) 69 (28) 104 (63)
RBC (6106/ml) 5.860.2 4.260.2, p,0.0001 4.860.3, p,0.0001 4.960.2, p,0.004 5.560.2, p = 0.55 6.160.3 p = 0.02
Hemoglobin (g/dl) 13.460.6 9.160.6, p,0.0001 11.260.7, p,0.0001 11.560.6, p,0.0001 12.860.5, p = 0.15 14.160.8, p = 0.11
Haematocrit % 43.962.0 29.861.7, p,0.0001 31.661.6, p,0.0001 31.861.6, p,0.0001 43.861.6, p = 0.91 46.762.7, p = 0.91
Mean corpuscular
volume (fl)
78.261.5 70.860.8, p,0.0001 65.360.9, p = 0.0001 64.860.9, p = 0.0001 79.861.4, p = 0.11 77.061.5, p = 0.21
Mean corpuscular
haemoglobin (g/dl)
23.960.4 21.660.3, p,0.0001 23.060.3 p,0.008 23.360.4 p = 0.07 23.460.6, p = 0.13 23.360.5 p = 0.21
Platelet counts
(6103/ml)
346.5613.1 183.5624.6 p = 0.002 406.5622.5 p = 0.05 390.7632.4, p = 0.11 332.2611.9, p = 0.78 294.3617.4 p = 0.55
WBC counts (6103/ml) 5.860.5 3.060.4, p = 0.003 7.161.0, p = 0.12 5.661.2, p = 0.9 5.960.8, p = 0.8 5.160.1, p = 0.4
Key: RBC = red blood cells; WBC = White blood cells; g/dl = grams/decilitre; fl = femtolitres; p-values,0.05 indicate values that were significantly different from pre-
infection baseline (day 0) values (Repeated measures Anova with Fishers PLSD post hoc test); Monkey were treated with DB844 at 6 mg/kg614 days, from 28–41 days
post infection.
doi:10.1371/journal.pntd.0001734.t003
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concentrations, accounts for the observation that trypanosomes
were eliminated more rapidly from the blood than from the CSF
(data not shown). An alternative dosing regimen in which higher
daily DB844 doses were administered once every two days as
discussed above could possibly result into more DB844/DB820
crossing the BBB and improve CNS activity as observed in the
GVR 35 mouse model [11]. The rationale for higher daily drug
doses would be based on the fact that drug transport across BBB is
influenced by concentration dependent passive diffusion, presence
of efflux aiding P-glycoprotein transporters or multidrug resis-
tance-associated protein transporter [37,38]. Importantly, howev-
er, structure activity relationship studies need to be continued to
identify molecules with superior activity against second stage
HAT.
No DB844-related haematological aberrations were observed in
the infected monkey model, indicating that low doses (5 and
6 mg/kg) were safe. Erythrocyte and platelet associated parame-
ters recovered rapidly indicating that erythropoesis and thrombo-
cytogenesis remained robust. White blood cells were similarly not
adversely affected, suggesting that DB844 was not myelotoxic.
However, trypanosome-induced anaemia, thrombocytopenia and
leucopoenia were observed. These are common features of
Figure 5. Transient infection and DB844 induced changes in clinical chemistry indicators of liver and kidney function. Symbols
represent mean 6 SE (n = 7) of aspartate aminotransferase (AST, &), alanine aminotransferase (ALT, %), total bilirubin (N), direct bilirubin (0), blood
urea nitrogen (BUN, m) and albumin (e); monkeys were treated with DB844 at 6 mg/kg614 days, from 28–41 days post infection.
doi:10.1371/journal.pntd.0001734.g005
Figure 6. Plasma concentration-time profiles following oral administration of the last (14th) daily dose of DB844. Symbols and error
bars represent geometric means and SEs, respectively, for DB844 (g) and DB820 (#). The monkeys (n = 7) were treated with DB844 at 6 mg/kg614
days, from 28–41 days post infection. The insert graph shows the extended profile up to 28 days post the last daily dose of DB844.
doi:10.1371/journal.pntd.0001734.g006
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experimental T.b. rhodesiense infections in monkeys [12,21,39] and
natural HAT infections in humans [40–42] whose severity is
determined by parasite virulence, time lag from infection to
therapeutic intervention and individual host differences. The
haematology changes before treatment were comparable to those
reported in previous infections with the KETRI2537 stabilate,
indicating good reproducibility of the monkey model. Further-
more, resolution of haematology aberrations such as haemoglobin
concentration and RDW was clearly related to treatment showing
that these were additional indicators of therapeutic efficacy. In un-
infected monkeys, the low dose regimen (5 mg/kg610 days)
similarly did not manifest haematologic toxicity. At high doses
(.10 mg/kg), however, bleeding and haemosiderosis were
observed in multiple organs possibly due to damage of endothelial
membranes, increased sequestration of damaged erythrocytes and
their subsequent destruction by tissue macrophages [43,44].
Clinical chemistry results (group II, efficacy study) showed
modest (2–3 fold) increases in plasma transaminases (AST and
ALT) but not alkaline phosphatase, consistent with hepatocellular
pathology. Importantly, these elevations in transaminases were
reversible within 4–7 days after the last drug dose, indicating that
they were likely caused by transient changes in the permeability of
hepatocyte cell membranes (rather than necrosis). In contrast high
doses (.10 mg/kg) caused significant hepatotoxicity that was
mainly characterized by fatty degeneration (steatosis), focal
necrosis, mononuclear infiltration and haemorrhages. Steatosis is
a common toxicity of many other drugs, including tetracyclines,
corticosteroids, non-steroidal anti-inflammatory drugs and diam-
idines [45–48]. Steatosis in the un-infected monkeys was likely
caused by impairment of mitochondrial fatty acid ß-oxidation
causing microvesicular steatosis and resulting in accumulation of
lipid vesicles in the cytoplasm of hepatocytes as previously
reported for other drugs [45–48].
Analysis of clinical chemistry indicators of renal pathology in
efficacy group II (6 mg/kg) monkeys revealed that blood urea
nitrogen (BUN) was minimally elevated while plasma creatinine
was not, indicating that kidney function was only transiently
affected. In contrast, histopathology results from the un-infected
monkeys revealed evidence of renal tubular degeneration in the 10
and 20 mg/kg, showing that a more significant renal pathology
resulted from the higher drug doses. Similarly, no lesions were
seen at low doses in the GIT while moderate to severe
gastroenteritis were observed at high doses. Overall therefore,
toxicity was dose-dependent and, taken together with results of the
efficacy study, indicated that there was a lack of therapeutic
window for DB844. As a result of toxicity, alternative dose
regimens to improve efficacy were not attempted.
In summary, this study showed that the prodrug DB844
achieved a moderate cure rate in the vervet monkey model of 2nd
stage HAT, which was in contrast with studies in mice in which
much higher DB844 doses (ie 100 mg/kg65 days) were tolerated
and cured all 5/5 mice [11]. This is perhaps the main reason why
new chemical entities (NCEs) that are targeted against HAT are
preferably evaluated in both rodent and monkey models to obtain
a more comprehensive understanding of safety, efficacy and
pharmacokinetics before being forwarded for clinical trials in man.
Although further development of DB844 against 2nd stage HAT
was discontinued due to the lack of a therapeutic window, DB844
has demonstrated that structural modifications of amidines could
eventually result in molecules with promising CNS activity at
tolerated dose levels. Indeed, novel amidine analogues with better
efficacy and safety profiles have been identified and are currently
being evaluated in this vervet monkey model of HAT, which will
be reported in due course.
Supporting Information
Figure S1 Individual monkey activity/concentration-
time profiles of aspartate amino transferase and blood
urea nitrogen in plasma. The monkeys were treated with
DB844 at 6 mg/kg614 days, from 28–41 days post infection with
T.b. rhodesiense KETRI2537.
(TIF)
Figure S2 Individual monkey concentration-time pro-
files of DB844 and DB820 in plasma. The monkeys were
treated orally with DB844 at 6 mg/kg614 days, from 28–41 days
post infection with T.b. rhodesiense KETRI2537. The insert graph
shows the extended profiles up to 28 days post the last daily dose of
DB844.
(TIF)
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Table 4. Pharmacokinetics of DB844 and DB820 in vervet
monkeys after the 14th oral dose at 6 mg/kg (n = 7).
Outcome Units DB844 DB820
AUC(0-‘) nmol/L?day 70 (16, 290) NC* NC
AUClast nmol/L?day 68 (16, 300) 1400 (760, 2500)
Metabolite: Parent
AUC Ratio
NA – – 3 (1.1, 6.5)
Cl/F L/day/kg 240 (56, 1000) NC NC
Cmax nmol/L 430 (100, 1800) 190 (110, 320)
t1/2 day 0.24 (0.14, 0.40) NC
{ NC
Tmax day 0.04 (0.04, 0.17) 0.17 (0.08, 0.17)
Key: Values are geometric mean (90% CI) except for metabolite:parent AUC
ratio and Tmax, which are reported as median (range). Metabolite:parent AUC
ratio was derived using the AUC from time zero to the last common time point
for DB844 and DB820.;
*% AUC extrapolated to infinite time .25%.
{Duration of sample collection was insufficient to derive an accurate estimate of
terminal half-life; AUC(0-‘), AUC from zero to infinite time; AUClast, AUC from
time zero to the last measurable concentration; Cl/F, apparent (oral) clearance;
Cmax, maximum concentration; t1/2, terminal half-life; Tmax, time to reach Cmax;
NA, not applicable; NC, not calculable.
doi:10.1371/journal.pntd.0001734.t004
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